The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

New study shows tirzepatide reduces LV mass and heart fat in obesity-related HFpEF, potentially improving heart failure outcomes.

Lilly's retatrutide shows remarkable weight loss in trials but raises concerns with side effects possibly linked to the drug like nausea and kidney stones. Read more here.

Weight loss medication has taken the world by storm ... driven by GLP-1 agents semaglutide and tirzepatide, as public interest influences prescription trends. This study presents TBorNotTB ...

To lose weight, you need to be in a calorie deficit. However, it's not as simple as consuming fewer calories. Depending on your physical activity, age, calories burned and more factors ...

"We believe the data from this study will demonstrate that the combination of MC4R + GLP-1/GIP agonists may result in additive and synergistic effects on patient weight loss, and importantly ...